TOKYO, May 12 (Pulse News Wire) – JMS CO.,LTD. (7702.T) reported lower revenue and profits for its fiscal year ending March 2026.
Consolidated revenue was 65,845 million yen, down from 69,749 million yen in the prior year. Operating profit fell to 381 million yen from 872 million yen last year. lower net profit attributable to shareholders was 783 million yen compared to a net income of 89 million yen previously. The decline in revenue was attributed to reduced sales in overseas markets, particularly in China and Africa, despite growth in domestic cancer treatment and nutrition areas.
Cost reduction measures helped mitigate some losses, but overall profitability suffered due to decreased demand for key products abroad. For the upcoming fiscal year, JMS forecasts revenue of 66,000 million yen and operating profit of 1,000 million yen. The company plans to focus on expanding its closed-system drug administration systems and anti-cancer medication delivery services, while also addressing rising raw material costs through price adjustments and operational efficiencies. JMS also announced a dividend plan of ¥15.50 per share, comprising an interim dividend of ¥7 and a final dividend of ¥8.50.
🟡 Confidence: Standard AI-translated content.